Ribomic (TSE:4591) Stock Based Compensation: 円0.00 Mil (TTM As of Mar. 2026)


TSE:4591 Ribomic Inc TSE:4591
30 GF Score
Price 円68.00
! 3 Warning Signs
View Full Analysis

What is Ribomic Stock Based Compensation?

Ribomic TSE:4591 +3.03% 30 Stock Based Compensation is 円0.00 Mil as of Mar. 2026. GuruFocus rates TSE:4591 with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Ribomic's Stock Based Compensation for the six months ended in Mar. 2026 was 円0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.00 Mil.

Ribomic Stock Based Compensation Related Terms

Ribomic Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Ribomic's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ribomic Stock Based Compensation Chart

Ribomic Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.11 6.59 6.26 1.95 2.04

Ribomic Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.43 1.95 0.00 0.00 0.00
TSE:4591
30GF Score
Ribomic Inc TSE:4591
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ribomic Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円0.00 Mil.

What does a Stock Based Compensation of 円0.00 Mil mean?
Ribomic (TSE:4591) has a Stock Based Compensation of 円0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ribomic and its competitors.
Is Ribomic's Stock Based Compensation too high?
Ribomic's current Stock Based Compensation is 円0.00 Mil. Overall, Ribomic has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ribomic's Stock Based Compensation compare to VRTX and REGN?
Ribomic's Stock Based Compensation of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ribomic and its competitors. Ribomic's current Stock Based Compensation is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ribomic stock overvalued right now?
Ribomic (TSE:4591) has a current Stock Based Compensation of 円0.00 Mil. The current Stock Based Compensation is 円0.00 Mil. Ribomic's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Ribomic (TSE:4591), the current Stock Based Compensation is 円0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ribomic Business Description

Address 3-16-13 Usui Building, Shirokanedai, Minato-ku, Tokyo, JPN, 108-0071
Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.
30GF Score

Get the complete analysis for TSE:4591

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円68.00
Price